10-Q: Leidos Holdings Reports Strong Q3 2024 Results, Driven by Growth in Health and Civil Sectors

• Leidos Holdings, Inc. reported a net income attributable to common stockholders of $364 million for the three months ended September 27, 2024, compared to a net loss of $399 million for the same period last year.
• The company's revenue increased to $4.19 billion for the quarter, up from $3.921 billion in the prior year.
• For the nine months ended September 27, 2024, net income attributable to common stockholders was $970 million, a significant improvement from a net loss of $30 million in the same period of 2023.
• The company's nine-month revenue reached $12.297 billion, compared to $11.458 billion in the prior year.
• The Health & Civil segment showed substantial growth, with a 73.9% increase in operating income for the quarter and a 98.1% increase for the nine-month period.
• The company's total backlog was $40.561 billion as of September 27, 2024, compared to $38.043 billion as of September 29, 2023.
• Approximately 66% of the remaining performance obligations are expected to be recognized over the next 12 months and 82% over the next 24 months.

Score: 8

Explanation: The document presents a positive outlook with strong financial results, particularly in the Health & Civil segment. The company's backlog and cash position are also strong. However, there are some risks related to government investigations and international operations, which temper the overall sentiment.

• Leidos experienced a significant increase in net income and revenue compared to the same period last year.
• The Health & Civil segment demonstrated strong growth in both revenue and operating income.
• The company's backlog increased, indicating future revenue potential.
• Leidos has a strong cash position with $1.185 billion in cash and cash equivalents.
• The company is in compliance with all debt covenants.
• The company has a $1 billion revolving credit facility available if required.

• The Commercial & International segment experienced a significant operating loss in the prior year, although it has improved this year.
• The company's effective tax rate increased for the three months ended September 27, 2024, compared to the same period last year.
• The company has ongoing government investigations and reviews that could have a material impact on the business.
• The company has $141 million in restricted cash.

• The company is subject to ongoing government investigations and reviews, which could result in penalties and reputational damage.
• The company's business is affected by the overall level of U.S. government spending and budget priorities.
• Failure to pass appropriation bills or a continuing resolution by December 20, 2024, could result in a federal government shutdown.
• International operations expose the company to regulatory and geopolitical risks.
• Changes in international trade policies, including higher tariffs, may increase procurement costs.
• The company's operations rely heavily on the sales and servicing of security and detection products, which have been negatively impacted by delays in airline travel infrastructure projects.

The company anticipates being able to meet its liquidity needs for the next 12 months through cash generated from operations, available cash balances, borrowings from its commercial paper program, and if needed, sales of accounts receivable and borrowings from its revolving credit facility.

• Management believes that the company has adequately reserved for potential adjustments from audits or reviews of contract costs.
• Management does not believe that outstanding performance guarantees and cross-indemnity agreements will have a material effect on the company's liquidity, capital expenditures, or financial condition.

Leidos operates in the government contracting industry, which is heavily influenced by government spending and budget priorities. The company's performance is tied to the demand for its services and products in national security, health, and other sectors. The company's realignment into four reportable segments reflects a strategic focus on specific capability sets.

• Leidos' revenue growth of 6.9% for the quarter and 7.3% for the nine months is comparable to other large government contractors, such as General Dynamics (GD) and Lockheed Martin (LMT), which have also seen moderate growth in recent periods.
• The company's operating margin of 12.3% for the quarter is within the range of industry averages, but the Health & Civil segment's margin of 23.4% is notably higher, indicating strong performance in that area.
• Leidos' backlog of $40.561 billion is a significant indicator of future revenue, and is comparable to the backlogs of other large government contractors.
• The company's debt-to-EBITDA ratio is within the required covenant limits, which is a positive sign of financial health, similar to other companies in the sector.

• Shareholders will benefit from the improved financial performance and share repurchases.
• Employees may be impacted by the ongoing investigations and reviews.
• Customers will benefit from the company's continued focus on innovation and technology solutions.
• Suppliers may be impacted by changes in international trade policies and tariffs.
• Creditors will be reassured by the company's strong financial position and compliance with debt covenants.

• The company will continue to monitor the impact of government spending and budget priorities.
• The company will continue to cooperate with ongoing government investigations and reviews.
• The company will continue to evaluate the impact of the Pillar Two legislation.
• The company will continue to execute its share repurchase program.

• The company is involved in various claims and lawsuits arising in the normal conduct of business.
• The company is subject to investigations and reviews relating to compliance with various laws and regulations.
• The company is conducting an internal investigation related to international operations and has self-reported to the Department of Justice and the Securities and Exchange Commission.
• The company received a Federal Grand Jury Subpoena related to a criminal investigation by the U.S. Attorneys Office for the Southern District of California.
• The company received a Federal Grand Jury Subpoena in connection with a criminal investigation being conducted by the U.S. Department of Justice Antitrust Division.

• March 10, 2023: Leidos entered into a Credit Agreement providing for a $1.0 billion term loan facility and a $1.0 billion revolving facility.
• December 20, 2024: Potential deadline for Congress to pass appropriation bills or another continuing resolution to avoid a federal government shutdown.
• September 27, 2024: End of the reporting period for the third quarter of 2024.
• October 22, 2024: Number of shares issued and outstanding of each of the issuers classes of common stock was 133,433,109 shares.
• October 29, 2024: Date of the report and certifications.